Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2025 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics’ Immunomodulator Clears Senescence

BURNABY, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation...
January 06, 2025 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics’ Immunomodulator Improves Fatty Liver Disease

BURNABY, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation...
December 16, 2024 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor

BURNABY, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
June 07, 2024 20:18 ET | Source: Qu Biologics, Inc.

Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly

Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial...
June 06, 2024 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer

BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
March 11, 2024 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics and TransBIOTech Awarded $450K Applied Research and Development Grant Funding

BURNABY, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
November 14, 2023 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics Receives Accelerating Clinical Trial (ACT) Funding for PERIOP-06 Clinical Trial

BURNABY, British Columbia, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
January 23, 2023 08:00 ET | Source: Qu Biologics, Inc.

Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics

BURNABY, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
December 14, 2022 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform

BURNABY, British Columbia, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
October 17, 2022 08:00 ET | Source: Qu Biologics, Inc.

Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly

BURNABY, British Columbia, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...

Next Page keyboard_arrow_right